Trials / Terminated
TerminatedNCT00844480
Efficacy and Safety of Zoledronic Acid in Acute Spinal Cord Injury: Prevention of Bone Loss
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Thomas J. Schnitzer · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a double-blind, randomized, placebo-controlled trial of zoledronic acid, 5mg, to be administered intravenously to people who have suffered an acute spinal cord fracture. The goal is to evaluate if zoledronic acid can prevent the acute bone loss seen in this population. Outcome measures will include bone density determinations over a one year period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | zoledronic acid | zoledronic acid, 5mg, iv |
| DRUG | placebo | iv |
Timeline
- Start date
- 2010-03-01
- Primary completion
- 2015-12-01
- Completion
- 2016-01-01
- First posted
- 2009-02-16
- Last updated
- 2017-06-14
- Results posted
- 2017-05-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00844480. Inclusion in this directory is not an endorsement.